🇺🇸 FDA
Pipeline program

AG-120 (Ivosidenib)

AG120-C-012

Phase 1 small_molecule completed

Quick answer

AG-120 (Ivosidenib) for Hepatic Impairment is a Phase 1 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
AGIOS PHARMACEUTICALS, INC.
Indication
Hepatic Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials